Comparative Treatment Outcomes for Idiopathic Subglottic Stenosis: 5-Year Update.
William S TierneyLi-Ching HuangSheau-Chiann ChenLynn D BerryCatherine AndersonMilan R AminMichael S BenningerJoel H BluminJonathan M BockPaul C BrysonPaul F CastellanosMatthew S ClarySeth M CohenBrianna K CrawleySeth H DaileyJames J DanieroAlessandro de AlarconDonald T DonovanEric S EdellDale C EkbomDaniel S FinkRamon A FrancoCatherine Gaelyn GarrettElizabeth A GuardianiAlexander T HillelHenry T HoffmanNorman D HogikyanRebecca J HowellMichael M JohnsJan L KasperbauerSid M KhoslaCheryl KinnardRobbi A KupferAlexander J LangermanRobert J LentzRobert R LorenzDavid G LottSamir S MakaniFabien MaldonadoLaura MatrkaAndrew J McWhorterAlbert L MeratiMatthew MoriJames L NettervilleKarla O'DellJulina OngkasuwanGregory N PostmaLindsay S RederSarah L RohdeBrent E RichardsonOtis B RickmanClark A RosenMatthew RohlfingMichael J RutterGuri S SandhuJoshua S SchindlerGlenn Todd SchneiderRupali N ShahAndrew G SikoraRobert J SinardMarshall E SmithLibby J SmithAhmed M S SolimanSigríður SveinsdóttirDavid VeiversSunil P VermaPaul M WeinbergerPhilip A WeissbrodChristopher T WoottenYu ShyrDavid O FrancisAlexander GelbardPublished in: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2023)
The North American Airway Collaborative (NoAAC) previously published a 3-year multi-institutional prospective cohort study showing variation in treatment effectiveness between 3 primary surgical techniques for idiopathic subglottic stenosis (iSGS). In this report, we update these findings to include 5 years of data evaluating treatment effectiveness. Patients in the NoAAC cohort were re-enrolled for 2 additional years and followed using the prespecified published protocol. Consistent with prior data, prospective observation of 487 iSGS patients for 5 years showed treatment effectiveness differed by modality. Cricotracheal resection maintained the lowest rate of recurrent operation (5%), followed by endoscopic resection with adjuvant medical therapy (30%) and endoscopic dilation (50%). These data support the initial observations and continue to provide value to providers and patients navigating longitudinal decision-making. Level of evidence: 2-prospective cohort study.